GABA Therapeutics commences phase I study of Etifoxine

January 16, 2020 Articles 7:21 pm

On Monday, GABA Therapeutics commenced dosing for its phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia. The phase I, two-stage, double-blind, placebo-controlled single and multiple dose study is evaluating the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy volunteers.

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit